Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
McKesson
McKinsey
Argus Health
Fish and Richardson
Harvard Business School
Chubb
Cipla
Farmers Insurance

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOLOFT

« Back to Dashboard

Clinical Trials for Zoloft

Trial ID Title Status Sponsor Phase Summary
NCT00000440 Sertraline and Naltrexone for Alcohol Dependence Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
NCT00000446 Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption and crime-related post-traumatic stress disorder in those individuals with both disorders. This will be a 12-week, placebo-controlled, double-blind outpatient trial. All subjects will receive cognitive behavioral therapy in addition to a placebo or sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and 6, 9, and 12 months after study entry.
NCT00000451 Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000451 Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) Completed Yale University Phase 2 This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000458 Sertraline and Cognitive Therapy in Depressed Alcoholics Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zoloft

Condition Name

Condition Name for Zoloft
Intervention Trials
Depression 31
Healthy 15
Major Depressive Disorder 15
Alcoholism 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zoloft
Intervention Trials
Depression 56
Depressive Disorder 50
Disease 29
Depressive Disorder, Major 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zoloft

Trials by Country

Trials by Country for Zoloft
Location Trials
United States 191
Canada 12
Australia 7
Spain 4
China 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zoloft
Location Trials
New York 20
California 19
Pennsylvania 15
Texas 11
North Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zoloft

Clinical Trial Phase

Clinical Trial Phase for Zoloft
Clinical Trial Phase Trials
Phase 4 46
Phase 3 14
Phase 2/Phase 3 5
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zoloft
Clinical Trial Phase Trials
Completed 84
Recruiting 15
Terminated 9
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zoloft

Sponsor Name

Sponsor Name for Zoloft
Sponsor Trials
National Institute of Mental Health (NIMH) 27
Pfizer 13
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zoloft
Sponsor Trials
Other 117
NIH 46
Industry 39
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Julphar
US Army
Cantor Fitzgerald
Fuji
Accenture
Cipla
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.